X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ZNTL

Closed

Zentalis Pharmaceuticals llc

15.19
+1.10 (+7.81%)
Last Update: 27 Mar 2024 23:00:00
Yesterday: 14.09
Day's Range: 14.065 - 15.24
Send
When Written:
 
17.59
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company that focuses on developing small-molecule drugs for the treatment of various types of cancer. The company was founded in 2014 and is headquartered in New York City.

Zentalis Pharmaceuticals is committed to discovering and developing innovative therapies that target cancer cells while sparing healthy cells. Their pipeline includes several drug candidates that are currently in clinical trials, including ZN-c5, ZN-c3, and ZN-d5.

ZN-c5 is a novel oral inhibitor of WEE1, a protein kinase that plays a key role in the DNA damage response pathway. ZN-c3 is a selective inhibitor of CDK9, a protein that regulates the transcription of genes involved in cancer cell growth and survival. ZN-d5 is a potent inhibitor of BCL-2, a protein that prevents cancer cells from undergoing apoptosis (programmed cell death).

Zentalis Pharmaceuticals is also developing a companion diagnostic test for ZN-d5, which will help identify patients who are most likely to benefit from treatment with the drug.

Overall, Zentalis Pharmaceuticals is focused on developing targeted therapies that have the potential to improve outcomes for cancer patients.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
When Written:
 
17.59
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company that focuses on the development of small molecule drugs for the treatment of cancer. The company was founded in 2014 and is headquartered in New York City. Zentalis' pipeline includes multiple drug candidates that target various types of cancer, including breast, ovarian, and prostate cancer. The company's lead drug candidate, ZN-c5, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of advanced solid tumors. Zentalis is committed to developing innovative treatments that can improve the lives of cancer patients.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:44.200.145.114
X